搜索到 1000 条关于 s59텔LEGO4989!코인DB상담✔️II 的文章

2018 版 CSCO 胃癌指南:更新要点一览

2018.04.23 2018 版 CSCO 胃癌指南:更新要点一览

、D2、R0 切除;基本策略 = I 级推荐术后辅助化疗 XELOX(1A 类)、S1 单药(1A 类);可选策略 = II 级推荐 FOLFOX(2A 类...大多对应 I 级推荐,可选策略大多对应 II 级或 III 级推荐,新增了证据类别。诊断方面的更新1. 影像诊断(1)分期诊断方面,内镜超声从可选策略上调为 I 级
老年人听力障碍或与认知功能下降相关

2015.06.16 老年人听力障碍或与认知功能下降相关

朵 0.5-4 HZ 的纯音听力频率平均值来界定听力阈值。听力可由此分为:≤ 25 dB 无听力障碍;26-40 dB 轻度听力障碍;>40 dB 中/重度听力障碍。研究发现,中/重度听力障碍者与无听力障碍者相比,其记忆与整体认知功能 20 年下降率有显著差别;而且,未佩戴助听器患者认知功能下降
新型 TKI(伏罗尼布)在晚期肾癌治疗中的临床应用

2025.12.16 新型 TKI(伏罗尼布)在晚期肾癌治疗中的临床应用

病例 155 岁,男性,2021 年因体检发现左肾占位入院。CT:1. 左肾下极占位性病变:肾 CA? 2. 双肺多发囊肿;3. 双肾小结石;4. 肝 S4 段强化灶;5. 肝多发囊肿。2021.10.14 行腹腔镜下左肾部分切除术。术后病理:乳头状肾细胞癌,II 型,ISUP 分级 G3 级。脉管内未见瘤栓,未见

2015.07.30 波恩大学 Uni Bonn

to be one of Germany's and indeed Europe's most important institutes... of the world's leading research based Universities and therefore
舒尼替尼未能改善肝细胞癌患者的总生存期

2013.12.26 舒尼替尼未能改善肝细胞癌患者的总生存期

肝细胞癌患者的总生存期比较研究要点: 本试验旨在评价舒尼替尼在晚期肝细胞癌中的疗效; 研究结果表明,舒尼替尼未能改善肝细胞癌患者的总生存期,与舒尼替尼相关的严重不良事件更高。舒尼替尼在肝细胞癌患者中的疗效是否优于或相当于索拉替尼目前还没有结论。为此,来自国立台湾大学医学院附属医院的郑安理教授等人做了一项开放的II ...

2013.09.04 功能性二尖瓣反流增NSTSEACS房颤风险

西班牙一项研究表明,非ST段抬高型急性冠脉综合征(NSTSEACS)后功能性二尖瓣反流常见,并可对预后产生不良影响。论文8月19日在线发表于《心脏》(Heart)。\r\n  此项前瞻性队列研究共纳入237例首次NSTSEACS后出院患者。受试者NYHA分级1~II,男性占74%,平均年龄66.1%。所有患者均在入院第一周接受心电图检查,并接受中位6.95年的超声心动图和临床随访。
回复:妇产科中级考试归来!

2013.05.27 回复:妇产科中级考试归来!

1.TBS分类:见不典型鳞状细胞:鳞状上皮异常 2.最常见的尿瘘:膀胱阴道瘘 3.SUI:压力性尿失禁 4.18岁少女,有原发性痛经:用前列腺素合成酶抑制剂 5.不属于垂体性闭经:PCOS 6.雌激素水平低落:II度闭经 7.还考了两张B超图,根据子宫内膜情况,决定治疗用药,有点...
回复:请考完副主任医师的战友来晒晒题

2012.10.01 回复:请考完副主任医师的战友来晒晒题

1.宫颈外口已脱出阴道口:子宫脱垂II轻 2.子宫脱垂鉴别诊断有:宫颈延长;阴道壁肿物;粘膜下肌瘤 3.绝经2年HRT治疗:雌孕激素序贯应用 4.外阴硬化性苔藓:外阴肛周皮肤萎缩变薄 5.外阴硬化性苔藓:治疗丙酸睾酮油膏 6.外阴鳞状细胞癌:最常见的外阴癌 7.经前期综合征治疗:...
口服干扰素加注射利巴韦林治疗丙肝的2期临床试验获阳性结果

2012.06.25 口服干扰素加注射利巴韦林治疗丙肝的2期临床试验获阳性结果

2012年6月14日,赛德医药科技和阿马里诺生物科技(OTCBB:AMAR)发表声明,其产品在台湾丙型肝炎病毒感染患者上进行的剂量范围II期临床研究得到了阳性的结果。一共169名病人(1b基因型)随机地服用500或1500国际单位(IU)天然人α干扰素(IFNa)口含片或相应的空白片24周,接下来24周不服药并进行观察。所有接受IFNa和Ribavirin注射24周的病人 ...
神经综述:手足口病的神经系统并发症

2018.06.06 神经综述:手足口病的神经系统并发症

://www.nhfpc.gov.cn/yzygj/s3594q/201805/5db274d8697a41ea84e88eedd8bf8f63.shtml...、止惊。(5)严密观察病情变化,密切监护。参考文献1. Esposito S, Principi N.Hand, foot and mouth disease
斑马鱼

2018.04.16 斑马鱼

://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd = Retrieve&db = pubmed&dopt = Abstract&list_uids... http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd = Retrieve&db
Clinical Endocrinology:肢端肥大症会引起耳炎和听力丧失

2012.03.05 Clinical Endocrinology:肢端肥大症会引起耳炎和听力丧失

)。共有43%的肢端肥大症患者出现了听力丧失,20%的患者至少有一只耳发生了耳炎。肢端肥大症患者和对照组的纯音平均中位数(PTA)分别为12.5 dB (范围: 2–72 dB)和8.3 dB (范围: 0–20 dB) (P < 0.001)。在患病的三个亚组中PTA没有显著差异
HBeAg 阳性的 HBVDNA 高载量老年患者,抗病毒该何去何从?

2020.01.06 HBeAg 阳性的 HBVDNA 高载量老年患者,抗病毒该何去何从?

/CO、HBcAb:8.97 S/CO 阳性,高敏 HBV-DNA:3.32×10^3IU/mL。彩超提示脂肪肝,左肾囊肿。肝硬度 CAP211dB.../CO、HBcAb:9.45S/CO 阳性,高敏 HBV-DNA:3.85×10^1 IU/mL。彩超提示脂肪肝,左肾囊肿。肝硬度 CAP203dB/m、E5.8Kpa
SFDA:警惕酮康唑口服制剂的严重肝毒性

2012.03.11 SFDA:警惕酮康唑口服制剂的严重肝毒性

,TB:1218umol/L,DB:546.1umol/L,ALT:89u/L,HCV阴性,PT:81.1s,PTA:23%,HBsAg阴性,经保肝、支持...,效果不佳。一周后出现全身浮肿入院,查肝功能:TB:500.8μmol/L,DB:340μmol/L,ALT:1096μ/L,AST
警惕酮康唑口服制剂的严重肝毒性

2011.08.31 警惕酮康唑口服制剂的严重肝毒性

,并逐渐加重入院,皮肤、巩膜重度黄染。检查肝功能,TB:1218umol/L,DB:546.1umol/L,ALT:89u/L,HCV阴性,PT:81.1s,PTA...、并出现尿黄,如浓茶色,偶有恶心、呕吐,予甘立欣、谷光甘肽等保肝、退黄治疗,效果不佳。一周后出现全身浮肿入院,查肝功能:TB:500.8μmol/L,DB
脑深部电刺激治疗阿尔茨海默病的初步探索(上)

2018.07.06 脑深部电刺激治疗阿尔茨海默病的初步探索(上)

图 1 封面图片阿尔茨海默病(Alzheimer’s disorder, AD)是一种中枢神经系统原发性退行性疾病,全世界约有 4600 万人患有痴呆症...(NCT01608061)临床试验研究结果已在《Journal of Alzheimer’s Disease》发表。Ⅰ期临床试验已证明 DBS 能够调节功能异常的

2012.09.19 【免注册费】上海分子流行病学与GWAS会议国际研讨会

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 分子流行病学再揭示人类复杂疾病遗传因素及其与环境因素相互作用发挥重要作用,为人类疾病的风险评估、预防和个性化治疗提供依据。全基因组关联分析(GWAS)为全面系统研究复杂疾病的遗传因素掀开了新的一页,为我们了解人类复杂疾病的发病机制提供了更多的线索。科学家已经在肥胖、糖尿病、冠心病、阿尔茨海默、乳腺癌、前列腺癌、肺癌、胃癌等一系列复杂疾病中进行了全基因组关联研究并找到疾病相关的易感基因,我国科学家也在银屑病、精神病和冠心病等方面开展了GWAS研究并取得成效。国家科技部最新公布了“常见重大疾病全基因组关联分析和药物基因组学研究”的863重点项目,吹响了我国大规模开展GWAS研究的号角。为了让更多的相关研究人员,特别是广大研究生了解GWAS的研究原理和方法,学会设计GWAS的研究和分析实验结果,同时在癌症领域分享海内外研究专家们的成功经验,并期待在GWAS方面进行交流合作,复旦大学和美国Van Andel 研究所将于2009年7月12-14日在上海联合举办上海分子流行病学与GWAS国际 研讨会, 期待各位同道免费参加,请有意者及时将回执返回联系邮箱。免注册费(食宿餐饮费用自理)。名额有限,报名从速!时间: 2009年7月12-14日
报到地点: 复旦大学卿云楼宾馆 上海市邯郸路220号,200433
会议地点: 复旦大学逸夫楼报告厅
联 系 人: 赵雪莹 高歌 联系电话: 021-55664495
回执邮箱: GWAS2009@gmail.com
&nbsp;BackgroundRecent success of genome-wide association studies (GWAS) in the U.S. and Europe has lead to the identification of a large number of genetic variants that are associated with disease risk and progression, including those for cancer and cardiovascular diseases. The discovery of these genetic markers not only improves our understanding of disease etiology, but also contributes significantly to risk prediction, early detection, and targeted treatment of diseases.Although GWAS have been used in Chinese populations to identify Chinese-specific risk-associated genetic variants for several common diseases such as breast cancer and psoriasis, many more GWAS are needed for various diseases. A better understanding of the importance of GWAS and a better knowledge of study design and data analysis of GWAS will further promote broad application of GWAS in China. This symposium which will cover genetic epidemiology and GWAS in China is organized to serve this purpose. We have invited a group of experts in this area from the U.S. and China to share their experience in GWAS, and we hope to foster an environment which will encourage an open discussion among all participants.
Objectives• To better understand the potential applications of GWAS
• To address practical issues in study design, implementation, and data analysis of GWAS
• To promote interaction and collaboration among researchers who are interested in GWAS
• To explore other important studies after GWAS: gene-environment interaction, risk prediction, and functional analyses
• To consider issues and implications related to genomic and personalize medicine
Organizing committeeThe organizing committee consists of four members:
Dr. Jianfeng Xu (Co-Chair)
Dr. Daru Lu (Co-Chair)
Dr. Li Jin (Co-Chair ,Advisor)
Dr. Qingyi Wei (Co-Chair, Advisor)
PresentationsSession I: Genetic epidemiology and GWAS of cancer
• Breast cancer in Chinese populations Xiao-ou Shu
• Genetic association studies of skin cancer Jiali Han
• Genetic variants in the MC1R gene and risk of cutaneous melanoma Qingyi Wei
• Genetic association studies of lung cancer in Chinese populations Daru Lu
• Molecular epidemiology of hepatitis, liver cirrhosis and hepatocarcinoma Gangqiao Zhou
• Molecular epidemiology of stomach cancer Weimin YeSession II: Genetic epidemiology and GWAS of other diseases
• Genetic association studies of hypertension in Chinese populations Jiang He
• GWAS of Autoimmune Diseases (Psoriasis, etc.) in Chinese populations Wei Huang
• Molecular epidemiology of diabetes in Chinese populations Weiping Jia
• Molecular genetics study of hypertension in Chinese populations Dingliang Zhu
• Molecular epidemiology of hepatitis, liver cirrhosis and hepatocarcinoma Gangqiao ZhouSession III: Post-GWAS studies
• Genetic structure of Chinese population Li Jin
• High-throughput genotyping for GWAS and fine mapping studies Siqun Lilly Zheng
• Molecular genetics study of neural tube defect Hongyan Wang
• Risk prediction using genetic variants in prostate cancer Jianfeng Xu
• Gene-environmental interaction in smoking related cancer Zuo-Feng Zhang
• Cancer Somatic Genomics Bin TehSession IV: Short presentations by participants and discussion
Registration时  间: 2009年7月12-14日
报到地点: 复旦大学卿云楼宾馆大厅 上海市邯郸路220号 (200433)
会议地点: 复旦大学逸夫楼报告厅
联 系 人: 赵雪莹,高歌 (Shanghai, China);Tamara Adams (U.S.)
联系电话: 21-55664495 (Shanghai, China);336-713-7532 (U.S.)
回执邮箱: GWAS2009@gmail.com (Shanghai, China);tsadams@wfubmc.edu (U.S.)
Invited speakers (alphabetic)• Jiali Han, Ph.D., is an Assistant Professor of Medicine at Harvard Medical School. His major research areas are:
• Genetic epidemiology of skin cancer and breast cancer
• Genome-wide association studies
• Gene-environment interaction• Jiang He, M.D. Ph.D., is a Professor and Chair of Epidemiology, Tulane University School of Public Health., U.S.A. His major research areas are:
• Genetic epidemiology of hypertension
• Gene-nutrition interaction of cardiovascular disease• Wei Huang, Ph.D., is a Professor and Executive Deputy Director of Chinese National Human Genome Center at Shanghai, China. Her major research areas are:
• Genetic susceptibility to autoimmune diseases, cardiovascular diseases and cancer.
• Genome-wide association studies
• Genetic variants and association study• Weiping Jia M.D., is a professor of endocrinology at Shanghai Institute of Diabetes, Shanghai No.6 People&rsquo;s Hospital, Shanghai Jiaotong University, Her major research area is:
• Molecular endocrinology and diabetes• Li Jin, Ph.D, is a Professor of Genetics and vice President of Fudan University, China. His major research areas are:
• Genetic and molecular epidemiology of lung cancer and glioma
• Genetics of metabolism diseases
• Genetic markers for population genetics• Daru Lu, Ph.D, is a Professor of Genetics and Vice Dean of School of Life Sciences, Fudan University, China. His major research areas are:
• Genetic and molecular epidemiology of lung cancer and glioma
• Genetics of metabolic disease• Xiao-ou Shu, M.D, Ph,D, is a Professor of Medicine in the Department of Medicine at the Vanderbilt University School of Medicine, U.S.A. Her major research areas are:
• Genetic and lifestyle predictors of cancer and other chronic diseases
• Cohort study methodology
• Incorporating biomarkers in risk prediction• Bin Teh, M.D, is a Distinguished Scientific Investigator at Van Andel Institute, U.S.A. His major research areas are:
• Translational cancer research
• Gene expression profiling
• Cancer genome high-throughput sequencing• Hongyan Wang, Ph.D, is a professor of genetics at School of Life sciences, Fudan University, China. Her major research area is:
• Molecular genetics and epidemiology of birth defects (deformity of neural tube, congenital heart disease, etc.)• Qingyi Wei, M.D, Ph.D, is a Professor of Epidemiology at The University of Texas M. D. Anderson Cancer Center, U.S.A. His major research areas are:
• Molecular epidemiology of DNA repair, apoptosis, and skin cancer and head and neck cancer
• Genetic susceptibility to cancer
• DNA repair and apoptosis phenotype markers• Jianfeng Xu, M.D, Dr.PH, is a Professor of Epidemiology and Cancer Biology and Director of the Center for Cancer Genomics at Wake Forest University School of Medicine, U.S.A. His major research areas are:
• Genetic epidemiology of prostate cancer
• Genome-wide association and fine mapping analysis
• Risk prediction using genetic markers and other clinicopathologic variables• Zuo-Feng Zhang, M.D., Ph.D, is a Professor of Epidemiology at UCLA School of Public Health, U.S.A. His major research areas are:
• Molecular epidemiology of smoking-related cancers
• Confirmation studies of SNPs identified in genome-wide association studies in smoking-related cancers
• Gene-environmental interaction between genetic markers and environmental factorsS. Lilly Zheng, M.D, is a Professor of Medicine and Director of the Genotyping Laboratory at Wake Forest University School of Medicine. U.S.A. Her major research areas are:
• High-throughput genotyping and sequencing
• Genetic epidemiology of prostate cancer• Gangqiao Zhou, Ph.D, is a Professor of Medical Genetics and Genomics in National Academy of Military Medical Science. His major research area is:
• molecular and genetics of complex diseases• Dingliang Zhu, M.D, is a professor of cardiology at Shanghai Institute of Hypertension, Shanghai, China. His major research area is:
• Molecular and genetics of cardiovascular diseases• Weimin Ye, Ph.D, is a Professor of Medical Epidemiology at Karolinska Institutet, Sweden. His major research areas are: Etiology of upper gastrointestinal diseases
• Topic of presentation: Molecular epidemiology of stomach cancer
&nbsp;
上一页 1 2 3 ... 46 47 48 49 50 下一页 到第